Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 6,087 shares of the company’s stock after purchasing an additional 537 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Moderna were worth $407,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna during the 2nd quarter worth approximately $26,000. Cedar Wealth Management LLC boosted its position in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Westside Investment Management Inc. purchased a new position in shares of Moderna during the 1st quarter worth approximately $32,000. Family Firm Inc. purchased a new position in shares of Moderna during the 2nd quarter worth approximately $33,000. Finally, Bank & Trust Co purchased a new position in shares of Moderna during the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Barclays decreased their price target on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research report on Monday, September 16th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target for the company. Jefferies Financial Group decreased their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $97.18.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Moderna news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the transaction, the director now owns 2,224,015 shares in the company, valued at $266,792,839.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,184 shares of company stock valued at $2,037,931 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Moderna Trading Down 0.0 %

NASDAQ MRNA opened at $53.39 on Thursday. The stock has a market capitalization of $20.46 billion, a P/E ratio of -3.41 and a beta of 1.66. Moderna, Inc. has a 52-week low of $52.77 and a 52-week high of $170.47. The firm has a 50-day moving average price of $69.03 and a 200 day moving average price of $103.55. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the prior year, the company posted ($3.62) earnings per share. Equities research analysts expect that Moderna, Inc. will post -9.85 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.